The Commission on Human Medicines has declared that the most popular diabetic drug be taken off the UK market. The Commission says its “risks outweigh its benefits.”
Recent research shows that the drug increases heart attack risk by 43 percent. And in the US, the drug maker is facing up to six billion dollars in legal suits. Yet an FDA panel has voted to keep it on the US market.